Novo Nordisk A/S President and CEO Lars Jorgensen mostly parried challenges to the company’s US pricing for its mega-blockbusters Ozempic and Wegovy at a Senate Health, Education, Labor and Pensions Committee hearing, using traditional counter arguments.
Senate Hearing On Ozempic, Wegovy Again Highlights Concerns About PBMs
Senate HELP Committee chair Sanders is trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices for Ozempic and Wegovy. Prominent Republican raises international reference pricing.
